Actually ADHD | Medication Strategies & Clinical Wisdom

The 2026 update to the most popular video on the Focus Path YouTube channel. Jonathan Murphy, PMHNP-BC, counts down the top 10 extended-release stimulant medications for adult ADHD based on clinical experience, accessibility, insurance coverage, and real-world outcomes.This is not a list from the internet. This is a ranking from a prescriber who has written thousands of these prescriptions and sees the results in his office every day. If it is not an extended-release stimulant, it is not on the list. If it is not accessible at the pharmacy, it drops in the ranking. If it requires splitting an atom to optimize, it drops in the ranking.The big four explained: Adderall XR and Vyvanse on the amphetamine side, Ritalin long-acting and Focalin XR on the methylphenidate side. Why Adderall XR is number one and Vyvanse is number six. Why Jornay PM earns number two despite the cost. Why Focalin XR would be first-line methylphenidate if insurance covered it. Why Concerta is number nine despite being the safest bet for coverage. Why Mydayis catches everybody. Why Metadate CD is the low-key option nobody talks about. Why Dexedrine Spansules is the sneaky option for UK listeners who do not have Adderall. And unlike Paris Hilton, nobody is paying me to say any of this.Send your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

Your ADHD medication is not going to do the heavy lifting for you. Jonathan Murphy, PMHNP-BC, breaks down the stage your medication needs to be set upon — the sleep, the food, the exercise, the environment, the phone, the planner — and why getting to all good no bad is only the beginning.This episode covers why one-a-day at the same time every day is the foundation, why your circadian rhythm matters even if you work night shift, why protein stabilizes your blood sugar and prevents the crash, why B12 deficiency can cause temporary paralysis, why iron carries the oxygen your brain needs, why picking up your phone before taking your medication is dumpster diving, why dopamine downregulation from scrolling undermines the medication before it starts, why the Pomodoro method is actually for stopping yourself when you are hyperfocused, why you still have ADHD even on medication, why the planner changed everything, and why the power of the pencil is the most underrated ADHD strategy that exists.Plan. Initiate. Reflect. Set the stage. The medication does the rest.Send your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

Time to reset. Jonathan Murphy, PMHNP-BC, strips ADHD back to its foundation and introduces the Stimulation Gap — the framework that explains why adults with ADHD cannot maintain a normative sleep-wake cycle or carry out basic functions of daily living without intervention.This episode covers what ADHD actually means for adults versus the version the internet sells, why the hyperactive-impulsive specifier is predominantly pediatric and often confused with mania in adults, why inattention and the novelty-crash cycle are the core adult presentation, why the stimulation gap accounts for the functional decline that separates ADHD from normal distraction, why ADHD treatment is a premium service that requires barriers, why context is everything with stimulant medication, why the first habit after medication matters more than the medication itself, and why the goal is to be here now.Also covered: the origin story of starting the ADHD clinic after grad school at Boston College, Heather saying “yeah I think you should,” William James on attention from 1890, the Russian doll of comorbidity, why the book was formatted with AI and why that does not change the value, playing Hotel California on guitar and why thinking about it was cooler than doing it, and why this sprint through the end of 2026 is about giving you the fundamentals so you can move on with your life.Send your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

Something happened overnight. Jonathan Murphy, PMHNP-BC, posted a podcast episode about generic ADHD medications and the pharmaceutical narratives behind them. Within hours, two comments arrived on two different YouTube videos defending two different pharmaceutical positions. One defended brand-name drugs. The other defended guanfacine. Both arrived the same night. Both escalated when challenged. Neither could answer a direct question.This episode covers what happened in those comment threads in real time, why the phrase “comparative RCT” is not something a YouTube viewer says, why a commenter who has never taken guanfacine argued for it across ten comments using pharmaceutical vocabulary, what happened when the question “are you on Takeda’s payroll” was asked and not answered three times, and what the SEC filings reveal about Takeda’s financial incentive to expand guanfacine into the adult ADHD market.Also covered: Amy Arnsten and Yale receiving royalties from Takeda on every Intuniv prescription, the ADHD Institute as a Takeda-funded educational platform, the $220 million annual revenue growing 105% year over year, the government alignment between pharmaceutical companies wanting to sell more guanfacine and healthcare systems wanting fewer stimulant prescriptions, and why the only question that matters is who benefits.First they ignore you, then they mock you, then they fight you, then you win. Send your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

There is a narrative online that generic ADHD medication is inferior. Jonathan Murphy, PMHNP-BC, follows the money and explains why that narrative exists, who benefits from it, and what the law actually says.The Hatch-Waxman Act of 1984 created the abbreviated pathway for generics. The brand company already proved the molecule works through clinical trials. The generic just has to prove it delivers the same molecule at the same rate into the bloodstream. That is bioequivalence. 90% of prescriptions filled in the US are generic. The FDA estimates Americans have saved $3 trillion since 2016 because of generics. Without them, the healthcare system collapses under drug costs.This episode covers why the word generic has become a synonym for lesser than, why brand companies have every incentive to undermine confidence in generics, the Morning Brew investigation by former NYT reporter Scott Carney, the Hatch-Waxman Act and what bioequivalence actually means, why Pfizer and Eli Lilly have been cited for the same impurity problems that get blamed on generics, why 53% of patented drugs are also produced overseas, and why the patient who insists on brand-only is asking for corporate dominance in a very scary way.A prescriber’s perspective: do not assume there is a problem when there is not one. Do not make your tires explode on a bumpy road. Focus on your symptoms, not the manufacturer on the bottle.

A listener asked how to go from one dose to the next without getting dropped by their prescriber. Jonathan Murphy, PMHNP-BC, breaks down the full titration logic, the system navigation mindset, and why the moment you start negotiating about drugs is the moment you lose.This episode covers why the system wants you to crash out and how not to let it, why your political energy needs to stay outside the appointment, why medication is not the same as using a drug, the difference between the adult starting dose and a dose that is too low, why you never go above the max dose, what horizontal moves are and when to make them, the methylphenidate ladder from Concerta to Ritalin LA to Metadate CD to dexmethylphenidate, why Aptensio is unnecessary, the amphetamine side with Adderall XR and Vyvanse, what to do when the medication stops working (it probably did not), Wellbutrin as an augmenting agent, why symptom language is the only language the system responds to, and why the goal is always all good no bad.The UK video is now live on the Focus Path YouTube channel.https://www.youtube.com/watch?v=A-HsiBNRqlcSend your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystems

The most requested topic on the channel. How do I know if my ADHD medication is working? Jonathan Murphy, PMHNP-BC, walks through the full medication trial process from first dose to maintenance dose, what to look for, what to ignore, and why the first week is not the answer.This episode covers why you cannot assess your medication in the first week, why the first month is the real baseline, what initial response actually means versus maintenance dose, why fatigue and crash are not a given, why extended-release capsules are the standard and immediate-release tablets are not, why a medication that works for less than 10-12 hours needs adjustment, why overstimulation tells you something different than poor response, the difference between amphetamine and methylphenidate responders, and why the goal is all good no bad.Also covered: the domains of functioning — industry, social life, physical, intellectual, creative — and why pencil to paper is step one. Why your foundation matters more than your medication. Why your in-laws visiting is not the medication failing. Why the ask-your-parents practice is ridiculous. And why someone who says “tell me what to do and I’ll do it” does the best.Send your ADHD questions to @ADHDAuthority on X. Questions answered on the podcast.The UK video drops within 24 hours.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

The companion podcast to the video that is making waves on the Focus Path YouTube channel. Jonathan Murphy, PMHNP-BC, breaks down the pharmaceutical pipeline behind Paris Hilton’s ADHD advocacy, tells the Disney World story he has never told publicly before, and names the creators who attended the Collegium-funded mansion party.Paris Hilton hosted 200 influencers at her Beverly Hills mansion for the Unstoppable ADHD Creator Summit. Every major media outlet covered it. Every outlet mentioned the same drug by name: Jornay PM. Nobody asked why.In 2025, a press release said it plainly. Paris Hilton collaborates with Collegium Pharmaceutical to share her personal ADHD journey and experience with treatment. Collegium makes Jornay PM. Jornay PM is projected to bring in $200 million this year.This episode covers the Hilton family fortune and why it was given to charity twice, the rebrand from The Simple Life to Embrace Your Sparkle, the five talking points that repeat across every media outlet, the Anti-Kickback Statute and why there is no law for the celebrity loophole, pharma dinners and what they are actually like from the inside, the Shire Disney World story, the Ironshore origin of Jornay PM, the payment map from Collegium to Paris to the nonprofit to the creators to the audience, and why the superpower language is everything we do not want mental health to be.Watch the video: https://www.youtube.com/watch?v=JExWhZxrRJwRead the article: https://www.myfocuspath.blog/p/paris-hilton-jornay-pm-and-modernThe Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

The DEA just scheduled centanafadine as Schedule III. The internet is about to lose its mind over this one. Jonathan Murphy, PMHNP-BC, breaks it down before the marketing noise drowns out the clinical reality.Simtriyo is a new ADHD medication approved by the FDA in July 2026, now scheduled by the DEA as of October 30, 2026. It is being marketed as a first-in-class triple reuptake inhibitor hitting norepinephrine, dopamine, and serotonin. The binding data tells a different story. The serotonin piece is likely not clinically relevant at therapeutic doses. The effect size is roughly one-third of traditional stimulants. No head-to-head trial against any existing ADHD medication was ever conducted. Two black box warnings: abuse potential and suicidality.This episode covers what Schedule III actually means versus Schedule II, how Otsuka Pharmaceutical developed the drug, why the triple reuptake inhibitor label is marketing language, why the serotonin claim is unproven, the abuse potential data from primate self-administration studies, why the suicidality warning matters for patients with mood instability, and why the honest clinical recommendation is to wait a year.The Process: An Adult’s Guide to ADHD Medication, available on AmazonFocus Path YouTube Channel: @FocusPathSystemsX (Twitter): @ADHDAuthority

Jonathan Murphy, PMHNP-BC, goes deep on the difference between ADHD and obsessive compulsive personality disorder, why the online ADHD conversation has gotten it wrong, and why men and women with ADHD are far more alike than the internet wants you to believe.This episode covers the three waves of ADHD content creators: the first wave of actual clinicians like Dr. Tracey Marks, the second wave of TikTok docs post-COVID, and what comes next. A direct critique of Dr. Sasha Hamdani’s identity-driven ADHD content and Ruri Ohama’s medication cessation narrative, and why personal storytelling about your own symptoms is not clinical education.The OCPD-ADHD overlap explained: the interruption in focus, the hyperfocus-crash cycle, unrealistic standards, perfectionism as relative safety, and why the core pathology matters more than the label. Egodystonic versus egosyntonic. Why the comorbidity question is always there.An introduction to the Survival Modality system through The General: the rage-shame cycle, the road rage archetype, why a female general and a male general carry the same attachment wound differently, and why the gender conversation misses the point that men and women share more inner experience than not.The episode ends where it began: regulate before you navigate. ADHD medication gets the brain online. Everything after that is the real work.